Acute Interstitial Pneumonia (Hamman-Rich Syndrome) in Lung Transplantation: A Case Series

Transplant Proc. 2022 Oct;54(8):2313-2316. doi: 10.1016/j.transproceed.2022.07.010. Epub 2022 Sep 6.

Abstract

Background: Acute interstitial pneumonia (AIP), also known as Hamman-Rich syndrome, is a rare and rapidly progressive idiopathic interstitial lung disease with a high mortality rate. Treatment is limited to supportive care and empirical high-dose steroids; however, outcomes are generally poor. There are few reports of lung transplantation (LTx) in patients with AIP.

Methods: We retrospectively identified patients with AIP among those who underwent LTx at our center between January 2008 and December 2020.

Results: During the study period, 4 patients with AIP underwent bilateral LTx: 3 men and 1 woman, between 30 and 57 years of age. The lung allocation score ranged between 71 and 89. Of the 4 patients, 2 needed extracorporeal membrane oxygenation and mechanical ventilation (MV) and 1 needed MV preoperatively. Time of onset to transplant ranged from 1 to 3 months. None of the patients had primary graft dysfunction after LTx; 2 had acute cellular rejection and 1 had chronic lung allograft dysfunction. The 4 patients are alive with survival ranging between 1 and 12 years after LTx.

Conclusion: AIP should be considered in patients with acute respiratory failure without a clear etiology. Our study showed that LTx led to good outcomes and should be considered as a treatment option in appropriate candidates.

MeSH terms

  • Extracorporeal Membrane Oxygenation*
  • Female
  • Hamman-Rich Syndrome*
  • Humans
  • Idiopathic Interstitial Pneumonias* / diagnosis
  • Idiopathic Interstitial Pneumonias* / surgery
  • Lung Transplantation* / adverse effects
  • Male
  • Retrospective Studies